Neutropenia and anaemia are serious complications of myelosuppressive chemotherapy. They have a negative impact on patient quality of life and may reduce response to treatment. Febrile neutropenia, a potentially life-threatening complication of neutropenia, frequently requires hospital admission, while fatigue and weakness from anaemia reduce patient's capacity for activity. Pegfilgrastim and darbepoetin alfa, were designed to simplify and optimise treatment for patients with cancer. Once-per-cycle pegfilgrastim is as effective as daily filgrastim with respect to duration of severe neutropenia (DSN) and may have a lower incidence of febrile neutropenia than filgrastim. Darbepoetin alfa has enhanced biological activity and a serum terminal half-life three-fold longer than that of erythropoietin (EPO), which translates into rapid and sustained correction of anaemia with less frequent dosing. These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives.

Optimising management of neutropenia and anaemia in cancer chemotherapy : advances in cytokine therapy / S. Siena, S. Secondino, L. Giannetta, O. Carminati, P. Pedrazzoli. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 48:Suppl(2003), pp. S39-S47. ((Intervento presentato al convegno Workshop on Geriatric Oncology: Focus on Myelodepression tenutosi a Siracusa nel 2002 [10.1016/j.critrevonc.2003.05.002].

Optimising management of neutropenia and anaemia in cancer chemotherapy : advances in cytokine therapy

S. Siena
Primo
;
S. Secondino;
2003

Abstract

Neutropenia and anaemia are serious complications of myelosuppressive chemotherapy. They have a negative impact on patient quality of life and may reduce response to treatment. Febrile neutropenia, a potentially life-threatening complication of neutropenia, frequently requires hospital admission, while fatigue and weakness from anaemia reduce patient's capacity for activity. Pegfilgrastim and darbepoetin alfa, were designed to simplify and optimise treatment for patients with cancer. Once-per-cycle pegfilgrastim is as effective as daily filgrastim with respect to duration of severe neutropenia (DSN) and may have a lower incidence of febrile neutropenia than filgrastim. Darbepoetin alfa has enhanced biological activity and a serum terminal half-life three-fold longer than that of erythropoietin (EPO), which translates into rapid and sustained correction of anaemia with less frequent dosing. These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives.
anaemia; cytokine; darbepoetin alfa; erythropoietin; granulocyte colony-stimulating factor; neutropenia; pegfilgrastim
Settore MED/06 - Oncologia Medica
2003
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S104084280300194X-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 106.88 kB
Formato Adobe PDF
106.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/676190
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact